GILD : Insider Transactions for Gilead Sciences Inc | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

Gilead Sciences Inc (GILD)

$64.27

0.19 (0.3%) as of 4:30 Fri 5/31

Download

Exchange:

Nasdaq National Market

Security Type:

Common

Shares Out:

1,250,000,000

Market Cap:

80.34(B)

Last Volume:

14,507,907

Avg Vol:

8,705,604

52 Week Range:

$63.5 - $87.29

Level I Sector:

Health Care

Level II Sector:

Drugs

Level III Sector:

Biotechnology

Member Indexes:

	S&P COMPOSITE 1500		NASDAQ BIOTECHNOLOGY
	NASDAQ COMPOSITE		NASDAQ-100
	S&P 500		NASDAQ NNM COMPOSITE

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : 259

Guru Rank Value : 4.6

Guru Occurances : 2


6 Months 1 Year 2 Year

Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	0	0
Total Buy Value	$0	$0	$0	$0
Total People Bought	0	0	0	0
Total Buy Transactions	0	0	0	0
Total Shares Sold	2,000	25,472	38,458	80,792
Total Sell Value	$145,920	$2,022,270	$3,052,046	$6,445,296
Total People Sold	1	3	3	4
Total Sell Transactions	1	5	9	14
End Date	2024-03-03	2023-12-01	2023-06-02	2022-06-02

Adjust Filter Settings

Records found: 1105

Page 26 of 45

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

Bischofberger Norbert W

EVP, R&D and CSO

• • –

2017-02-16

4

GD

$0.00

$0

D/D

11,558

12,453

-

Bischofberger Norbert W

EVP, R&D and CSO

• • –

2017-02-16

4

D

$70.31

$497,092

D/D

(7,070)

24,011

-

Bischofberger Norbert W

EVP, R&D and CSO

• • –

2017-02-16

4

A

$0.00

$0

D/D

8,794

31,081

-

EVP Comm&Acs ALA, Corp&Med Aff

• • –

2017-02-16

4

D

$70.31

$462,429

D/D

(6,577)

124,418

-

EVP Comm&Acs ALA, Corp&Med Aff

• • –

2017-02-16

4

A

$0.00

$0

D/D

7,716

130,995

-

Washington Robin L

EVP, CFO

• • –

2017-02-15

4

A

$59.33

$18,689

D/D

315

21,519

-

EVP Worldwide Commercial Ops

• • –

2017-02-15

4

A

$59.33

$12,637

D/D

213

6,939

-

Milligan John F

President and CEO

• • –

2017-02-15

4

A

$59.33

$18,689

D/D

315

1,059,278

-

Executive Chairman

• • –

2017-02-15

4

A

$59.33

$18,689

D/D

315

3,131,411

-

Bischofberger Norbert W

EVP, R&D and CSO

• • –

2017-02-15

4

A

$59.33

$18,689

D/D

315

22,287

-

EVP Comm&Acs ALA, Corp&Med Aff

• • –

2017-02-15

4

A

$59.33

$18,689

D/D

315

123,279

-

Chief Operating Officer

• • –

2017-02-15

4

A

$59.33

$18,689

D/D

315

2,881

-

Chief Operating Officer

• • –

2017-02-10

4

D

$66.36

$21,036

D/D

(317)

2,566

-

Chief Operating Officer

• • –

2017-02-10

4

OE

$0.00

$0

D/D

908

2,883

-

Executive Chairman

• • –

2017-02-01

4

AS

$72.57

$5,322,069

D/D

(73,333)

3,131,096

-

Executive Chairman

• • –

2017-02-01

4

OE

$21.58

$1,582,159

D/D

73,333

3,204,429

-

Chief Operating Officer

• • –

2017-02-01

4

D

$72.82

$15,656

D/D

(215)

1,975

-

Chief Operating Officer

• • –

2017-02-01

4

OE

$0.00

$0

D/D

620

2,190

-

Executive Chairman

• • –

2017-01-03

4

AS

$73.04

$5,396,971

D/D

(73,337)

3,131,096

-

Executive Chairman

• • –

2017-01-03

4

OE

$21.58

$1,582,246

D/D

73,337

3,204,433

-

Director

• • –

2016-12-01

4

OE

$0.00

$0

D/D

2,147

107,486

-

Executive Chairman

• • –

2016-12-01

4

AS

$73.33

$7,332,870

D/D

(100,000)

3,131,096

-

Executive Chairman

• • –

2016-12-01

4

OE

$16.40

$1,639,500

D/D

100,000

3,231,096

-

Bischofberger Norbert W

EVP, R&D and CSO

• • –

2016-11-22

4

GD

$0.00

$0

I/I

10,000

2,306,849

-

Moore Nicholas G

Director

• • –

2016-11-21

4

GD

$0.00

$0

D/D

3,406

11,882

-

1105 Records found	Previous 20 21 22 23 24 25 26 27 28 29 Next	Page 26 of 45

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2024 j3sg.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.